STOCK TITAN

Genenta Science (NASDAQ: GNTA) regains Nasdaq minimum bid price compliance

Filing Impact
(Neutral)
Filing Sentiment
(Neutral)
Form Type
6-K

Rhea-AI Filing Summary

Genenta Science S.p.A. reports that it has regained compliance with Nasdaq’s minimum bid price requirement. Nasdaq Listing Rule 5550(a)(2) requires a minimum bid price of $1.00 per share for continued listing.

Nasdaq notified Genenta on April 10, 2026 that the closing bid price of its American Depositary Shares had been below $1.00 per share for 30 consecutive business days, placing the company out of compliance. Nasdaq has now determined that from June 1, 2026 through June 12, 2026, the closing bid price was at or above $1.00 per share for 10 consecutive business days, restoring compliance and closing the matter.

Positive

  • Nasdaq compliance regained: Genenta restored compliance with Nasdaq Listing Rule 5550(a)(2) after its ADSs traded at or above $1.00 for 10 consecutive business days, removing an active minimum bid price deficiency.

Negative

  • None.

Insights

Genenta removes an immediate Nasdaq delisting risk by restoring bid-price compliance.

Genenta Science regained compliance with Nasdaq Listing Rule 5550(a)(2) after its American Depositary Shares closed at or above $1.00 for 10 consecutive business days from June 1–12, 2026. This resolves the earlier deficiency notice tied to a 30-day period below the threshold.

Maintaining Nasdaq listing status is important for trading liquidity and institutional access, so resolving a bid-price issue can be meaningful for shareholders. Actual long‑term impact will depend on whether the share price remains above the $1.00 minimum in future periods.

Nasdaq minimum bid price $1.00 per share Required under Nasdaq Listing Rule 5550(a)(2)
Non-compliance period length 30 consecutive business days Closing bid below $1.00 per share before April 10, 2026 notice
Compliance restoration period 10 consecutive business days Closing bid at or above $1.00 from June 1–12, 2026
Initial Nasdaq notice date April 10, 2026 Date Nasdaq notified Genenta of bid price deficiency
Compliance confirmation date range June 1–12, 2026 Period used by Nasdaq to confirm restored compliance
Nasdaq Listing Rule 5550(a)(2) regulatory
"regained compliance with Nasdaq Listing Rule 5550(a)(2), which requires listed securities"
minimum bid price financial
"requires listed securities on Nasdaq to maintain a minimum bid price of $1.00 per share"
The minimum bid price is the lowest share price that a market, regulator, or specific offering will accept for a trade, listing, or auction—think of it as a reserve or floor that a stock must meet to qualify for certain actions. It matters to investors because falling below that floor can limit trading options, trigger compliance measures or delisting risks, and affect liquidity and the perceived value of a holding, much like a reserve price in an auction sets the baseline for a sale.
American Depositary Shares financial
"the closing bid price of the Company’s American Depositary Shares (“ADSs”) had been below $1.00"
American depositary shares (ADSs) are a way for investors in the United States to buy shares of foreign companies without dealing with international markets directly. They represent ownership in a foreign company's stock and are traded on U.S. stock exchanges, making it easier for American investors to buy, sell, and own parts of companies from around the world.
Form 6-K regulatory
"This report on Form 6-K is incorporated by reference into the registrant’s registration"
A Form 6-K is a report that companies listed in certain countries file to provide important updates, such as financial results, corporate changes, or other significant information, to regulators and investors. It functions like an official company update or news release, helping investors stay informed about developments that could affect their investment decisions.
See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google
Learn about SEC filing dates

 

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

 

 

 

FORM 6-K

 

REPORT OF FOREIGN PRIVATE ISSUER

PURSUANT TO RULE 13a-16 OR 15d-16 UNDER

THE SECURITIES EXCHANGE ACT OF 1934

 

For the month of June 2026

 

Commission File Number: 001-41115

 

GENENTA SCIENCE S.P.A.

(Translation of registrant’s name into English)

 

Via dell’Annunciata 31

20121 Milan, Italy

(Address of Principal Executive Offices)

 

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.

 

Form 20-F ☒ Form 40-F ☐

 

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1): ☐

 

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): ☐

 

This report on Form 6-K is incorporated by reference into the registrant’s registration statement on Form S-8 (File No. 333-278392).

 

 

 

 
 

 

Other Events

 

Genenta Regains Compliance with Nasdaq Minimum Bid Price Requirement

 

On June 15, 2026, Genenta Science S.p.A. (the “Company”) received a letter from the Listing Qualifications Department of The Nasdaq Stock Market LLC (“Nasdaq”) notifying the Company that it has regained compliance with Nasdaq Listing Rule 5550(a)(2), which requires listed securities on Nasdaq to maintain a minimum bid price of $1.00 per share.

 

As previously disclosed in the Current Report on Form 6-K of the Company filed on April 14, 2026 with the U.S. Securities and Exchange Commission, on April 10, 2026, Nasdaq notified the Company that the closing bid price of the Company’s American Depositary Shares (“ADSs”) had been below $1.00 per share over the previous 30 consecutive business days and that the Company was therefore not in compliance with the minimum bid price requirement. Nasdaq has now determined that, for the 10 consecutive business days from June 1, 2026 through June 12, 2026, the closing bid price of the Company’s ADSs was at or above $1.00 per share. Accordingly, Nasdaq has formally notified the Company that it has regained compliance with Listing Rule 5550(a)(2) and that the matter is closed.

 

 
 

 

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

  GENENTA SCIENCE S.P.A.
     
  By: /s/ Pierluigi Paracchi
  Name: Pierluigi Paracchi
  Title: Chief Executive Officer

 

Dated: June 16, 2026

 

 

 

FAQ

What did Genenta Science (GNTA) announce in this Form 6-K?

Genenta Science announced it has regained compliance with Nasdaq’s minimum bid price rule. Nasdaq confirmed the company’s ADSs closed at or above $1.00 per share for 10 consecutive business days, resolving a prior deficiency notice and closing the matter.

Which Nasdaq rule did Genenta Science (GNTA) regain compliance with?

Genenta regained compliance with Nasdaq Listing Rule 5550(a)(2), which requires a minimum bid price of $1.00 per share. Nasdaq confirmed the company satisfied this standard over 10 consecutive business days, restoring its status under the rule.

Why was Genenta Science (GNTA) previously out of compliance with Nasdaq?

Genenta was previously out of compliance because the closing bid price of its ADSs stayed below $1.00 per share for 30 consecutive business days. Nasdaq notified the company of this deficiency on April 10, 2026, triggering the need to cure the issue.

How did Genenta Science (GNTA) regain Nasdaq minimum bid price compliance?

Genenta regained compliance after Nasdaq determined that from June 1, 2026 through June 12, 2026, the closing bid price of its ADSs was at or above $1.00 per share for 10 straight business days, satisfying the minimum bid price requirement.

What does resolving the Nasdaq bid price issue mean for Genenta Science (GNTA) shareholders?

Resolving the bid price issue means Nasdaq has closed the compliance matter, reducing immediate listing risk. Continued adherence to the $1.00 minimum bid price requirement remains important for trading liquidity and maintaining access to the Nasdaq Capital Market.